AR094203A1 - Formulacion farmaceutica en n-[5-[2-(3,5-dimetoxifenil)etil]-2h-pirazol-3-il]-4-[(3r,5s)-3,5-dimetilpiperazin-1-il]benzamida - Google Patents

Formulacion farmaceutica en n-[5-[2-(3,5-dimetoxifenil)etil]-2h-pirazol-3-il]-4-[(3r,5s)-3,5-dimetilpiperazin-1-il]benzamida

Info

Publication number
AR094203A1
AR094203A1 ARP130104937A ARP130104937A AR094203A1 AR 094203 A1 AR094203 A1 AR 094203A1 AR P130104937 A ARP130104937 A AR P130104937A AR P130104937 A ARP130104937 A AR P130104937A AR 094203 A1 AR094203 A1 AR 094203A1
Authority
AR
Argentina
Prior art keywords
dimethylipiperazin
dimetoxifenil
benzamida
pirazol
etil
Prior art date
Application number
ARP130104937A
Other languages
English (en)
Inventor
Baker Noel
Mistry Alpesh
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49998566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR094203(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR094203A1 publication Critical patent/AR094203A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicación 1: Una composición farmacéutica que comprende más de un 10% p/p del compuesto de fórmula (1) y una cantidad de un agente efervescente alcalino que sea suficiente para proporcionar una disolución satisfactoria in vitro; y que comprende además uno o más ingredientes farmacéuticamente aceptables. Reivindicación 5: Una composición farmacéutica de acuerdo con cualquiera de las reivindicaciones precedentes, donde el agente efervescente es carbonato de magnesio. Reivindicación 8: Una composición farmacéutica de acuerdo con las reivindicaciones 7 y 8, donde el lubricante alternativo es dibehenato de glicerilo.
ARP130104937A 2012-12-21 2013-12-19 Formulacion farmaceutica en n-[5-[2-(3,5-dimetoxifenil)etil]-2h-pirazol-3-il]-4-[(3r,5s)-3,5-dimetilpiperazin-1-il]benzamida AR094203A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261740520P 2012-12-21 2012-12-21

Publications (1)

Publication Number Publication Date
AR094203A1 true AR094203A1 (es) 2015-07-15

Family

ID=49998566

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130104937A AR094203A1 (es) 2012-12-21 2013-12-19 Formulacion farmaceutica en n-[5-[2-(3,5-dimetoxifenil)etil]-2h-pirazol-3-il]-4-[(3r,5s)-3,5-dimetilpiperazin-1-il]benzamida

Country Status (26)

Country Link
US (2) US20140179712A1 (es)
EP (1) EP2934494B1 (es)
JP (1) JP6328138B2 (es)
KR (1) KR20150096787A (es)
CN (1) CN104853750B (es)
AR (1) AR094203A1 (es)
AU (1) AU2013366023B2 (es)
BR (1) BR112015014200A2 (es)
CA (1) CA2893480C (es)
CL (1) CL2015001786A1 (es)
CR (1) CR20150320A (es)
DO (1) DOP2015000127A (es)
ES (1) ES2742400T3 (es)
HK (1) HK1212229A1 (es)
IL (1) IL239521A0 (es)
MX (1) MX368670B (es)
NI (1) NI201500087A (es)
PE (1) PE20151418A1 (es)
PH (1) PH12015501389A1 (es)
RU (1) RU2674978C2 (es)
SG (1) SG11201504769WA (es)
TW (1) TWI651085B (es)
UA (1) UA115342C2 (es)
UY (1) UY35244A (es)
WO (1) WO2014096828A1 (es)
ZA (1) ZA201505197B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140179712A1 (en) 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide
WO2024031226A1 (zh) * 2022-08-08 2024-02-15 无锡和誉生物医药科技有限公司 Fgfr抑制剂的药物组合物、多晶型物及其在药学上的应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB843940A (en) 1955-09-27 1960-08-10 Kodak Ltd Method of processing photographic silver halide emulsions containing colour couplers
BE667399A (es) 1964-07-30 1965-11-16
JPS57150846A (en) 1981-03-13 1982-09-17 Konishiroku Photo Ind Co Ltd Photographic element
JPS63133152A (ja) 1986-11-26 1988-06-04 Konica Corp 新規なマゼンタカプラ−を含有するハロゲン化銀写真感光材料
JPH0467645A (ja) 1990-07-09 1992-03-03 Nec Kyushu Ltd バーンイン装置
US5292520A (en) * 1990-09-13 1994-03-08 Akzo N.V. Stabilized solid pharmaceutical composition containing acid addition salts of a basic drug and an alkaline stabilizer
JP2890065B2 (ja) 1990-11-10 1999-05-10 コニカ株式会社 ハロゲン化銀写真感光材料
JPH04184437A (ja) 1990-11-20 1992-07-01 Fuji Photo Film Co Ltd カラー画像形成方法及びハロゲン化銀カラー写真感光材料
JPH04292322A (ja) 1991-03-19 1992-10-16 Fujitsu Ltd ラック給排装置
JPH0511414A (ja) 1991-07-02 1993-01-22 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
CA2119155C (en) 1991-10-18 1999-06-15 Dennis Paul Phillion Fungicides for the control of take-all disease of plants
EP0586686A1 (en) 1992-03-26 1994-03-16 Dowelanco N-heterocyclic nitro anilines as fungicides
HRP921338B1 (en) 1992-10-02 2002-04-30 Monsanto Co Fungicides for the control of take-all disease of plants
TW240217B (es) 1992-12-30 1995-02-11 Glaxo Group Ltd
JP3156026B2 (ja) 1993-12-27 2001-04-16 株式会社大塚製薬工場 ホスホン酸ジエステル誘導体
EP0788358B1 (en) 1994-11-10 2004-03-31 Millennium Pharmaceuticals, Inc. Use of pyrazole compounds for the treatment of glomerulonephritis, cancer, atherosclerosis or restenosis
FR2745500B1 (fr) 1996-03-04 1998-04-03 Synthelabo Formulations pharmaceutiques a liberation prolongee contenant de la mizolastine
EA003056B1 (ru) 1996-12-23 2002-12-26 Дюпон Фармасьютикалз Компани АЗОТСОДЕРЖАЩИЕ ГЕТЕРОАРОМАТИЧЕСКИЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Ха, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ
EP1012150A4 (en) 1997-05-19 2002-05-29 Sugen Inc HETEROARYLCARBOXAMIDE COMPOUNDS THAT ARE EFFECTIVE OF DISEASES CAUSED BY PROTEIN-TYROSIN-KINASE
CA2288787A1 (en) 1997-05-22 1998-11-26 G.D. Searle And Co. Pyrazole derivatives as p38 kinase inhibitors
US6271237B1 (en) 1997-12-22 2001-08-07 Dupont Pharmaceuticals Company Nitrogen containing heteromatics with ortho-substituted P1s as factor Xa inhabitors
JP3310226B2 (ja) 1998-10-16 2002-08-05 松下電器産業株式会社 音声合成方法および装置
GB9823103D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
WO2000047558A1 (fr) 1999-02-10 2000-08-17 Welfide Corporation Composes amide et leur utilisation medicinale
AU3357700A (en) 1999-02-16 2000-09-04 E.I. Du Pont De Nemours And Company Phenoxypyrimidine insecticides and acaricides
WO2001012621A1 (en) 1999-08-13 2001-02-22 Vertex Pharmaceuticals Incorporated INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES
EP1202733B1 (en) 1999-08-12 2005-10-05 Pharmacia Italia S.p.A. 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents
ES2279769T3 (es) 1999-09-24 2007-09-01 Smithkline Beecham Corporation Mimeticos de trombopoyetina.
US20050209297A1 (en) 2000-08-31 2005-09-22 Pfizer Inc Pyrazole derivatives
WO2002024656A1 (fr) 2000-09-22 2002-03-28 Nihon Nohyaku Co., Ltd. Derives de n-(4-pyrazolyl amide, produits chimiques pour utilisation agricole et horticole et applications desdits derives
EA011719B1 (ru) 2000-12-18 2009-04-28 Институт Оф Медисинал Молекьюлар Дизайн, Инк. Ингибитор высвобождения воспалительного цитокина
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
JP2004538266A (ja) 2001-04-27 2004-12-24 バーテックス　ファーマシューティカルズ　インコーポレイテッド ピラゾール由来のキナーゼインヒビター
IS1935B (is) * 2002-03-19 2004-06-16 Actavis Group Hf. Fósínópríl lyfjasamsetning
EA008769B1 (ru) 2002-06-05 2007-08-31 Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. Лекарственное средство для лечения диабета
JPWO2003103658A1 (ja) 2002-06-05 2005-10-06 株式会社医薬分子設計研究所 免疫関連プロテインキナーゼ阻害剤
WO2003103665A1 (ja) 2002-06-06 2003-12-18 株式会社医薬分子設計研究所 抗アレルギー薬
US20060004010A1 (en) 2002-07-10 2006-01-05 Hiromu Habashita Ccr4 antagonist and medical use thereof
AU2003253686A1 (en) 2002-08-01 2004-02-23 Pharmacia & Upjohn Company Llc 1h-pyrazole and 1h-pyrrole-azabicyclic compounds with alfa-7 nachr activity
DE602004028907D1 (de) 2003-02-06 2010-10-14 Bristol Myers Squibb Co Als kinaseinhibitoren geeignete verbindungen auf thiazolylbasis
EP1620108B1 (en) 2003-05-01 2012-06-06 Bristol-Myers Squibb Company Pyrazole-amine compounds useful as kinase inhibitors
US20040220170A1 (en) 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
US7115359B2 (en) 2003-07-25 2006-10-03 Konica Minolta Medical & Graphic, Inc. Photothermographic material
JP4795237B2 (ja) 2003-08-21 2011-10-19 オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー Ｎ−置換ピラゾリル−アミジル−ベンズイミダゾリルｃ−Ｋｉｔ阻害剤
US7432271B2 (en) 2003-09-02 2008-10-07 Bristol-Myers Squibb Company Pyrazolyl inhibitors of 15-lipoxygenase
US20050171172A1 (en) 2003-11-13 2005-08-04 Ambit Biosciences Corporation Amide derivatives as PDGFR modulators
JP4864719B2 (ja) 2003-11-26 2012-02-01 ファイザー・プロダクツ・インク Ｇｓｋ−３インヒビターとしてのアミノピラゾール誘導体
US7652146B2 (en) 2004-02-06 2010-01-26 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors
GB2411355B (en) * 2004-02-27 2006-02-22 Niche Generics Ltd Pharmaceutical composition
US7253204B2 (en) 2004-03-26 2007-08-07 Methylgene Inc. Inhibitors of histone deacetylase
EP1751133B1 (en) 2004-04-28 2010-04-14 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
CA2615890A1 (en) 2005-08-02 2007-02-08 Irm Llc 5-substituted thiazol-2-yl amino compounds and compositions as protein kinase inhibitors
EP1945190A1 (en) * 2005-09-22 2008-07-23 Swissco Devcelopment AG Effervescent metformin composition and tablets and granules made therefrom
IS2385B (is) * 2006-02-10 2008-07-15 Actavis Group Hf. Klópidógrel bísúlfat lyfjasamsetningar
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
PL386051A1 (pl) * 2008-09-09 2010-03-15 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Stabilna doustna kompozycja farmaceutyczna zawierająca farmaceutycznie dopuszczalną sól kwsu [(E)-7-[4-(4-fluorofenylo)-6-izopropylo-2-[metylo(metylosulfonylo)amino]pirymidyn-5-ylo] (3R,5S)-3,5-dihydroksyhept-6-enowego
CN102740836A (zh) * 2009-04-24 2012-10-17 伊休蒂卡有限公司 用于制备商品化纳米颗粒和微粒粉末的方法
JP5614557B2 (ja) * 2009-05-27 2014-10-29 ダサン メディケム カンパニー リミテッド 発泡層を含む多層錠剤
EP2464340A2 (en) * 2009-08-12 2012-06-20 Valeant International (Barbados) SRL Pharmaceutical compositions with tetrabenazine
WO2012052757A1 (en) * 2010-10-20 2012-04-26 Astrazeneca Ab Tumour phenotype patient selection method
US20140179712A1 (en) 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide

Also Published As

Publication number Publication date
CR20150320A (es) 2015-09-11
EP2934494B1 (en) 2019-06-12
CL2015001786A1 (es) 2015-08-14
CA2893480C (en) 2021-01-12
MX2015008067A (es) 2016-04-25
KR20150096787A (ko) 2015-08-25
AU2013366023B2 (en) 2016-10-27
US10420764B2 (en) 2019-09-24
CA2893480A1 (en) 2014-06-26
AU2013366023A1 (en) 2015-06-18
WO2014096828A1 (en) 2014-06-26
MX368670B (es) 2019-10-10
CN104853750A (zh) 2015-08-19
NI201500087A (es) 2016-02-16
PH12015501389A1 (en) 2015-09-02
EP2934494A1 (en) 2015-10-28
TWI651085B (zh) 2019-02-21
CN104853750B (zh) 2018-06-26
PE20151418A1 (es) 2015-10-21
JP2016503782A (ja) 2016-02-08
HK1212229A1 (en) 2016-06-10
DOP2015000127A (es) 2015-07-31
UA115342C2 (uk) 2017-10-25
RU2674978C2 (ru) 2018-12-14
JP6328138B2 (ja) 2018-05-23
BR112015014200A2 (pt) 2017-07-11
RU2015126345A (ru) 2017-01-30
SG11201504769WA (en) 2015-07-30
TW201431553A (zh) 2014-08-16
IL239521A0 (en) 2015-08-31
ES2742400T3 (es) 2020-02-14
US20140179712A1 (en) 2014-06-26
UY35244A (es) 2014-01-31
US20170119759A1 (en) 2017-05-04
ZA201505197B (en) 2017-07-26

Similar Documents

Publication Publication Date Title
ES2524320T3 (es) Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo
NI201700073A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
BR112014004460A2 (pt) material polimérico para um recipiente isolado
CL2012002317A1 (es) Compuestos derivados de tienopirimidinas, inhibitores de quinasas mnk1/mnk2; composicion farmaceutica; y su uso para elt ratamiento o profilaxis de enfermedades metabolicas, tales como diabetes, daño renal, cancer, enfermedades inflamatorias, entre otras.
CL2012002319A1 (es) Compuestos derivados de amino-tienopirimidinas que contienen un grupo alquilo sustituido, inhibidores de mnk| o mnk2; composición farmacéutica; y su uso para la profilaxis o la terapia de enfermedades metabólicas, trastornos hematopoyéticos, enfermedades neurodegenerativas, cáncer, entre otras.
AR088381A1 (es) Formulaciones de etanercept estabilizadas con meglumina
PE20140255A1 (es) Tableta dispersable en forma oral
BR112015011430A2 (pt) composição para liberação imediata e prolongada
MX362807B (es) Formulacion estabilizada de pemetrexed.
BR112014020113A8 (pt) Composições farmacêuticas e método para diminuir a frequência de micção
BR112014032759A2 (pt) composições lipídicas de racecadotril
BR112013019394A2 (pt) uso de um agente
AR091739A1 (es) Composiciones y metodos para reducir el riesgo cardiometabolico
AR085042A1 (es) Composiciones de cuidado oral con extracto de magnolia
CL2012003341A1 (es) Composicion farmaceutica de administracion oral que compende bendamustina o un ester, una sal o un solvato de la misma, y un excipiente que es un agente tensioactivo no ionico e hidrofilico; combinacion farmaceutica; y su uso para el tratamiento de leucemia linfocitica cronica y el mieloma multiple, entre otras enfermedades.
RU2009128593A (ru) Средства борьбы с паразитами животных
UY29365A1 (es) Nueva forma de sal de un agonista de dopamina
AR087371A1 (es) Formulaciones de (trimetoxifenilamino)pirimidinilo, metodos
AR094203A1 (es) Formulacion farmaceutica en n-[5-[2-(3,5-dimetoxifenil)etil]-2h-pirazol-3-il]-4-[(3r,5s)-3,5-dimetilpiperazin-1-il]benzamida
MX2017007856A (es) Composicion para el cuidado bucal.
DOP2019000199A (es) Agente terapéutico oral tiroidal
PE20130381A1 (es) Composicion farmaceutica solida para administracion bucal de agomelatina
AR110957A1 (es) Agente terapéutico oral para tiroides
UA113233U (uk) Пероральна фіксована комбінація теноксикаму і снодійного або заспокійливого компонента
ES2505716T1 (es) Composiciones farmacéuticas que comprenden una sal de ácido

Legal Events

Date Code Title Description
FB Suspension of granting procedure